Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab subcutaneous 52-week study in uncontrolled eosinophilic asthma
2015-000865-29Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and eosinophilic asthma (EA) comparing Reslizumab with Placebo (2 arms). Primary endpoint: Frequency of clinical asthma exacerbations per patient during the 52-week treatment period. Started Jul 2015; status: completed.
02
Drugs
reslizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2015-000865-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000865-29.